India, Jan. 27 -- Being a whole-virus vaccine doesn't give Bharat Biotech product any advantage at this stage, say experts
Bharat Biotech International Ltd, Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV) published a preprint paper January 26 claiming Covaxin worked against the novel coronavirus variant that sprang up in the United Kingdom.
The paper said 38 blood sera samples had been collected from Covaxin recipients who had returned from the UK. Researchers found the neutralisation capacity of the antibodies against the UK variant was similar to that of the homologous variant otherwise circulating in India as well as two others found in the country.
"Sera from the vaccine recipients could neutralise ...